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Main Points 
The incidence of vancomycin-resistant enterococci infections increased in Atlanta and Detroit but did 
not increase in national samples. VRE infection is associated with large attributable burdens, including 
excess mortality, prolonged in-hospital length of stay, and increased treatment costs. 
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Abstract 
Background: Information about the health and economic impact of infections caused by vancomycin-
resistant enterococci (VRE) can inform investments in infection prevention and development of novel 
therapeutics. Our objective was to systematically review the incidence of VRE infection in the US and the 
clinical and economic outcomes of these infections. 
Methods: We searched various databases for US studies published between 1/1/2000 and 6/8/2015 
that evaluated incidence, mortality, length of stay (LOS), discharge to a long-term care facility (LTCF), 
readmission, recurrence, or costs attributable to VRE infections. We included multicenter studies that 
evaluated incidence and single center and multicenter studies that evaluated outcomes. We kept 
studies that did not have a denominator or uninfected controls only if they assessed post-infection LOS, 
costs, or recurrence. We performed meta-analysis to pool the mortality data. 
Results: Five studies provided incidence data and 13 studies evaluated outcomes or costs. The incidence 
of VRE infections increased in Atlanta and Detroit but did not increase in national samples. Compared 
with uninfected controls, VRE infection was associated with increased mortality (pooled odds ratio 
2.55), longer LOS (3 - 4.6 days longer or 1.4 times longer), increased risk of discharge to a LTCF (2.8 to 
6.5-fold) or readmission (2.9-fold), and higher costs ($9,949 higher or 1.6-fold more). 
Conclusions: VRE infection is associated with large attributable burdens, including excess mortality, 
prolonged in-hospital stay, and increased treatment costs. Multicenter studies that use suitable controls 
and adjust for time at risk or confounders are needed to estimate the burden of VRE infections 
accurately. 
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Abbreviations 
HAI, healthcare-associated infections; LOS, length of stay; LTCF, long-term care facility; VRE, 
vancomycin-resistant enterococci. 
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Introduction 
Vancomycin-resistant enterococci (VRE) infections are endemic in hospitals across the US [1]. VRE are 
the second most common antimicrobial resistant pathogens causing healthcare-associated infections 
(HAIs) in the US [2, 3]. According to the National Healthcare Safety Network (NHSN) data in 2009 – 2010, 
38.6% of enterococci isolated from device-associated HAIs and 23.1% of those isolated from surgical site 
infections (SSIs) were vancomycin resistant [3]. 
Multiple epidemiological investigations of VRE infections have been published; however most prior 
studies were performed before newer antibiotics such as quinupristin-dalfopristin, linezolid, or 
daptomycin were used widely [4]. Most studies that reported the incidence of VRE infections were 
completed at single centers and evaluated small patient populations. Additionally, some studies claiming 
to report the incidence of VRE infections did not report a denominator-based incidence rate but instead 
reported the proportion of enterococcal isolates from infections that were vancomycin resistant [5, 6]. 
Furthermore, only a few studies evaluated outcomes, and some of these studies either included  both 
colonized patients and infected patients or included patients infected with vancomycin-susceptible 
enterococci (VSE) as the comparator and did not include an uninfected control group [4 ,7]. Studies that 
use patients with VSE infections as the comparator can assess only the impact of antimicrobial 
resistance, but not the effect of antimicrobial resistance in addition to the infection itself [8]. 
To address gaps in our understanding about the current burden associated with VRE infections in the 
US, we conducted a systematic literature review of studies that were conducted in the US, were 
published during or after 2000, and reported the incidence of VRE infections or outcomes related to 
these infections. Our goals were to describe the recent incidence of VRE infections, and to evaluate the 
clinical and economic outcomes attributable to VRE infections. 
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Methods 
Search Strategy 
We conducted a systematic review according to the Meta-analysis of Observational Studies in 
Epidemiology [9] and the Preferred Reporting Items for Systematic Reviews and Meta-Analyses [10] 
guidelines. See supplementary document for a detailed description of the search strategy. We reviewed 
reference lists from each article we retrieved to identify additional studies. 
Inclusion and Exclusion Criteria 
Studies were included if they: 1) were conducted in the US, 2) reported data from any year from 2000 
through 2015, and 3) evaluated the incidence of VRE infections or outcomes attributable to VRE 
infections, including mortality, length of stay (LOS), discharge to a long-term care facility (LTCF), 
readmission, recurrence, or costs. We included multicenter studies that had at least 8 sites when we 
assessed the incidence of VRE infections. For studies presenting outcome data, we included single 
center studies because most multicenter studies that assessed outcomes evaluated the same patient 
population (Detroit Medical Center, DMC). We excluded studies that: 1) used the International 
Classification of Diseases, 9th Revision, Clinical Modification (ICD-9-CM) diagnosis codes to define VRE 
infections, 2) combined patients with VRE colonization with those who had infections, 3) did not report 
original data, 4) did not have a denominator or an uninfected control group, or 5) were published in a 
language other than English. We included studies that did not have an uninfected control group if they 
assessed the post-infection (after the first positive culture of VRE) outcomes of LOS, costs, or 
recurrence. For LOS or costs, we excluded studies if they did not measure post-infection LOS or costs, or 
did not match cases with controls on either the time at risk (time from admission to infection for cases, 
time from admission to discharge for uninfected controls), or on propensity scores. The current study 
did not require Institutional Review Board approval. 
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Data Extraction and Quality Assessment 
Dr. Chiang reviewed the titles and abstracts of all articles to determine if they met the inclusion criteria. 
For each included study, 2 of 4 reviewers (Drs. Chiang, Nair, Perencevich, Schweizer) independently 
abstracted data on: study design, population, setting, location, definition of VRE infection, incidence 
data, and clinical and economic outcomes. Reviewers resolved disagreements by consensus. We 
assessed the risk of bias using the Newcastle-Ottawa tool [11] for all studies and the Consensus Health 
Economic Criteria [12] for studies evaluating costs. 
Meta-Analysis of Mortality 
We performed a meta-analysis of the studies that provided mortality data. We abstracted adjusted odds 
ratios (aORs) from the literature or raw data when aORs were not available. We pooled data using both 
random-effects and fixed-effects models with inverse variance weighting, and we used the Cochran Q 
statistic and the I2 statistic to assess heterogeneity. Publication bias was determined by visually 
evaluating the funnel plot.  
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Results 
We screened 7,324 unique studies for eligibility (Figure 1). Eighteen studies were eligible for inclusion 
including: 5 multicenter studies reporting the incidence of VRE infections [2, 13-16] and 13 studies (4 
multicenter and 9 single center) evaluating relevant outcomes [17-29]. 
Five studies used the NHSN definition of hospital-acquired VRE infections [2, 15, 21-23], 8 studies 
included patients with VRE recovered from sterile sites [13, 16, 17, 20, 25, 27-29], 4 studies included 
patients with VRE recovered from sterile sites or urine [14, 18, 19, 26], and 1 study did not define VRE 
infection [24]. Overall, the risk of bias among all studies evaluated was low (Table 1). 
Incidence of VRE infections 
The incidence varied by study location, population, and the denominator used (i.e., person-years, 
patient-days, device-days, or number of hospitalizations) (Table 2). Thus, we could not calculate a 
summary incidence estimate. The incidence of VRE infections in Atlanta increased from 0.77 per 100,000 
person-years in 1997 to 1.60 per 100,000 person-years in 2000 (P = 0.001). The increasing trend was 
significant in the African Americans but not in the White residents, and the overall incidence was 
significantly higher in the African Americans than in the White populations (2.59 vs 0.70 per 100,000 
person-years) [13]. Among patients admitted to the 8-hospital DMC system, the incidence of VR E. 
faecalis infections increased from 0.72 per 1,000 patient-days in 2003 to 1.68 per 1,000 patient-days in 
2009 (P < 0.001), and the incidence of VR E. faecium increased from 1.97 to 2.67 per 1,000 patient-days 
(not statistically significant) [14]. Consistent with previous literature, VR E. faecium caused a higher 
proportion of the infections than did VR E. faecalis in Atlanta (83% vs 6%) [13] and in southeast Michigan 
area (71% vs 29%) [14].  
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Among patients admitted to all Veterans Affairs (VA) hospitals, the incidence of VRE decreased between 
2007 and 2010 from 1.51 to 0 per 1,000 patient-days for patients admitted to ICUs (P < 0.001) and 
decreased from 0.33 to 0.09 per 1,000 patient-days for patients admitted to non-ICU units (P < 0.001) 
[15]. Between 2005 and 2011, the incidence of VRE infections did not change significantly among 
Medicare patients with 1 of the 4 conditions (i.e., acute myocardial infarction, congestive heart failure, 
pneumonia, or conditions requiring surgery) [16].  
NHSN reported that the pooled incidence of VR E. faecium central-line associated bloodstream (BSIs) 
infections during 2006 and 2007 was 0.18 (range: 0.06 to 0.37) per 1,000 device-days in ICUs and 0.14 
(range: 0.13 to 0.15) per 1,000 device-days in non-ICUs. The pooled incidence of VR E. faecium catheter-
associated urinary tract infections was 0.14 (range: 0.05 to 0.18) per 1,000 device-days in ICUs and 0.25 
(range: 0.12 to 0.45) per 1,000 device-days in non-ICUs [2]. 
Outcomes attributable to VRE infections 
Table 3 summarizes the results of 13 studies that reported outcomes or costs attributable to VRE 
infections. The 3 multicenter studies from DMC used different subgroups of patients: BSIs caused by VR 
E. faecalis or VR E. faecium in 2008 – 2010 [17], all VR. E faecalis infections in 2008 – 2009 [18], and all 
community-onset (CO) VR E. faecalis in 2008 – 2009 [19]. The study populations of the single center 
studies included all hospitalized patients [21], patients with liver transplants or stem cell transplants [24, 
28], non-surgical patients [25], or patients with leukemia [29]. Five studies evaluated only VRE BSIs [17, 
21, 25, 28, 29], 1 study evaluated CO VRE infections [19], and 2 studies evaluated all VRE infections [18, 
24]. 
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Mortality 
Figure 2 summarizes the ORs from 6 studies that reported mortality data. These studies included a total 
of 1,182 VRE-infected patients and 1,840 uninfected controls. Compared with uninfected controls, 
patients who had VRE infections had a 2.5-fold higher risk of death (random-effects model; pooled OR 
[pOR] = 2.55; 95% CI [1.91, 3.39]). The heterogeneity among studies was negligible (P = 0.54 for Q 
statistic test and I2 = 0%). The funnel plot (Figure 3) was not consistent with publication bias. The pooled 
mortality estimate from the 4 single center studies [21, 24, 28, 29] was higher (pOR = 3.15; 95% CI [2.15, 
4.60]) than the estimates from the 2 multicenter studies (OR = 1.81; 95% CI [1.06, 3.08] and OR = 2.20; 
95% CI [1.04, 4.65]) [18, 19], which was not surprising because small single center studies often 
overestimate true effects.  
Post-infection LOS and LOS attributable to VRE 
Five studies that did not include uninfected control patients found post-infection LOS ranging from 9 to 
22 days. The median post-infection LOS for patients with VRE BSI ranged from 9.1 to 13 days in 2 
multicenter studies [17, 20] and was 17 days in a single center study [23]. In 2 other single center 
studies, the post-infection LOS for patients infected with linezolid-resistant or -intermediate VRE was 3 
to 4 days longer than that for patients infected with linezolid-susceptible VRE (median 13 vs 9 days [26]; 
mean 22 vs 19 days [27]). 
Four studies assessed LOS attributable to VRE infections by either matching infected patients and 
uninfected patients on time at risk or by matching on propensity scores. These studies found that LOS 
for patients with VRE infections was 3 to 4.6 days (median difference) longer [18, 19, 25] or 1.4 times 
(multiplicative increase) longer [21], than for uninfected patients. 
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Discharge to a LTCF 
Two multicenter studies evaluated the likelihood that patients admitted to DMC from home would be 
discharged to LTCFs. Compared with uninfected patients, patients with VR E. faecalis infections had a 
2.8-fold increased risk (11.4% vs 33.9%) [18] of being discharged to a LTCF and patients with CO VR E. 
faecalis infections had a 6.5-fold increased risk (4.7% vs 26.3%) [19]. 
Readmission 
Only one multicenter study evaluated readmissions associated with VRE infections. The authors found 
that patients with VR E. faecalis infections were 2.9-fold more likely to be readmitted within 6 months 
(after the first culture positive for VRE for infected cases and after admission for uninfected controls), 
compared with matched controls (74.5% vs 50.8%) [18]. 
Recurrence 
Two studies evaluated recurrence rates. Of patients treated for VRE BSI in VA centers, 23.6% had 
recurrences within 60 days after completing treatment [20]. Fifteen percent of patients treated for VR E. 
faecium at a cancer center had recurrences within 30 days [22]. 
Costs 
Two single center studies evaluated costs associated with VRE infections and matched on either time at 
risk [21] or propensity score [25]. Song et al. found that the costs of a hospital admission were $124,257 
for patients with VRE BSIs and $46,699 for uninfected controls. The adjusted analysis showed that the 
costs for patients with VRE BSIs were 1.6-fold higher than the costs for uninfected controls [21]. Butler 
et al. found that the costs for non-surgical patients with VRE BSIs were $9,949 USD more than the costs 
for uninfected patients [25].  
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Discussion 
Our systematic literature review found that the incidence of VRE infections varied by study. Patients 
with VRE infections were more likely to die in the hospital, to have longer hospital stays, to be 
discharged to LTCFs after being admitted from home, to be readmitted within 6 months, and to have 
higher hospital costs compared with uninfected patients. 
Incidence 
Two studies assessing the incidence of VRE infections in individual metropolitan areas found that the 
incidence increased during their study periods [13, 14]. In addition, the VRE infection incidence was 
significantly higher among African Americans than among White residents in Atlanta. The investigators 
postulated that African Americans had a higher rate of chronic conditions, which increased their need 
for healthcare and, thereby, increased their risk for staphylococcal infections and vancomycin exposure 
[13].  
A study among a subset of Medicare patients that had few VRE infections found stable VRE infection 
rates during 2005 – 2011 [16]. The findings of this study may indicate that the incidence of VRE 
infections among low risk populations has not changed significantly since 2000. In contrast, a study of all 
VA patients found that the incidence of VRE infections and methicillin-resistant Staphylococcus aureus 
(MRSA) infections decreased during 2007 – 2010, after VA hospitals implemented a bundle to decrease 
MRSA HAIs [15]. The decline in VRE infections may have been related to the decline in MRSA infections 
and less frequent use of vancomycin or to improved overall infection prevention practices associated 
with the MRSA intervention.  
To avoid misclassification bias, we did not include studies that used ICD-9-CM diagnosis codes (V09.80, 
V09.81, 041.04) to define VRE infection [30-34]. Administrative coding was designed for billing not 
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research. Prior studies have shown that codes for acute conditions such as infections often overestimate 
the incidence of these conditions [35, 36]. To our knowledge, no published study has validated the ICD-
9-CM codes for either VRE or enterococcal infection with lab-confirmed VRE infection. Until they have 
been validated, these codes should not be used to estimate the burden of VRE infections. 
Most VRE infections in US are caused by enterococcal isolates that have the VanA plasmid, which carries 
the vancomycin-resistant gene. This plasmid occurs more commonly in VR E. faecalis than in other 
species of Enterococcus and may be transferred to S. aureus, causing the isolates to become vancomycin 
resistant (VRSA) [37, 38]. As of May 2015, 8 of 14 VRSA infections in the US occurred in southeastern 
Michigan, where the incidence of VR E. faecalis is higher than other regions [18, 37]. Thus, monitoring 
the regional incidence of VRE could help public health officials assess the potential for emergence and 
spread of VRSA. 
Mortality 
Our study, which compared the risk of mortality among VRE infected patients with uninfected patients, 
found that VRE infection was significantly associated with mortality (pOR = 2.55). Three prior meta-
analyses also evaluated mortality among VRE infected patients but used patients with VSE infections as 
their comparison groups. Two of these meta-analyses only included studies that were conducted before 
2003, when newer antimicrobial agents such as daptomycin, linezolid, and quinupristin-dalfopristin 
were not widely available. The first meta-analysis of 13 studies found that patients with VRE BSI had a 2-
fold higher risk of mortality compared with patients that had VSE BSI [4]. The second meta-analysis, 
which assessed 9 studies and adjusted for severity of illness, found that patients with VRE BSI were 2.5 
times more likely to die than patients with VSE BSI [38]. The third meta-analysis only included studies 
that were published after the approval of new antimicrobial agents effective against VRE [39]. That 
meta-analysis compared patients with VRE infections with those who had VSE infections and found a 
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smaller unadjusted association between VRE infection and mortality (pOR = 1.80; 95% CI [1.38, 
2.35]).Our meta-analysis evaluated studies published during the same time period as the third meta-
analysis. However, we assessed studies that used uninfected controls, which likely explains the stronger 
association we found between mortality and VRE infection. In addition, VSE and VRE have relatively low 
virulence. Kaye et al. previously found that the effect of clinical outcomes associated with MRSA SSIs 
was 2 to 3-fold greater when uninfected patients were used as controls than when patients with MSSA 
SSIs were used [8]. Whereas, clinical outcomes of VRE wound infections were similar when controls 
were uninfected or when they were infected with VSE. They postulated that the magnitude of the effect 
was related to the virulence of the pathogen being studied. 
Other Outcomes 
We found that the attributable hospital LOS was 3 – 4.6 days or 1.4 times longer and the attributable 
cost was $10,000 USD or 1.6-fold more for patients with VRE infections than those for uninfected 
controls. Our estimates are likely to be less biased than those of prior studies because we included 
studies that used uninfected controls that matched on the time at risk [18, 19, 21] or on a propensity 
score [25]. Studies that do not account for the time from admission to infection overestimate the LOS 
attributable to the infection because of time-dependent bias. Nelson et al. performed a systematic 
review to estimate the magnitude of time-dependent bias [40]. They compared the conventional 
method of calculating excess LOS attributable to HAIs with that calculated after matching patients on 
time at risk. They found that estimates of the LOS calculated by conventional methods were on average 
12.6 days longer or 139% greater than those generated when controls were matched on time to 
infection. Similarly, studies that do not account for patient characteristics in the analyses or do not 
match on propensity scores may overestimate the LOS or cost attributable to VRE because patients 
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infected with resistant organisms often have severe underlying diseases, which are independently 
predictive of adverse outcomes and increased costs. 
Limitations 
Our study has several potential limitations. First, the definition of VRE was not consistent across studies. 
Second, we could not pool incidence data because denominators and study populations varied by study. 
Third, the Newcastle-Ottawa risk of bias tool was not useful because the questions about comparability 
and outcome assessment were not applicable to the incidence studies and the questions about selection 
of non-infected controls and comparability were not applicable to studies including only VRE infected 
patients. However, we do not think these limitations would cause us to underestimate or overestimate 
the burden of VRE infections. 
Conclusion 
VRE infections still increase mortality, hospital LOS, and costs in the US despite the current treatment 
options and infection prevention measures. Most published studies evaluating outcomes attributable to 
VRE infections had small sample sizes or did not consider the time at risk or confounders. In addition, 
many studies assessed outcomes attributable to vancomycin-resistance instead of those attributable to 
VRE infections. However, our study, which evaluated studies that used uninfected patients as controls, 
found that VRE infection was associated with poor outcomes. Our study provides valuable information 
about the current burden of VRE infections in the US and identified gaps that should be addressed by 
future studies, so that we can estimate accurately the incidence and outcomes attributable by VRE 
infections. 
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Figure Titles and Footnotes (see attachments for figures) 
Figure 1. Flow diagram of search strategy 
ICD-9, International Classification of Diseases, 9th Revision; LOS, length of stay; LTCF, long-term care 
facility; VRE, vancomycin-resistant enterococci.  
Figure 2. Forest plot of six studies providing mortality data [18, 19, 21, 24, 28, 29] 
Figure 3. Funnel plot of six studies providing mortality data [18, 19, 21, 24, 28, 29] 
  
23 
 
Table 1. Risk of bias assessment using Newcastle-Ottawa tool [11].  
 Selection Comparability Outcome 
Author (Year) Representativeness of infected cases 
Selection of the 
non-infected 
controls 
Ascertainment 
of infection 
Outcome was not 
present at the 
beginning of study 
Case and 
controls 
comparability 
Assessment of 
outcome 
Follow-up long 
enough for 
outcome to occur 
Adequacy of 
follow up of 
cohort 
Studies that assessed incidencea 
Camins (2007) [13] * * * NA NA NA NA NA 
Hidron (2008) [2] * * * NA NA NA NA NA 
Hayakawa (2011) [14] * * * NA NA NA NA NA 
Jain (2011) [15] * * * NA NA NA NA NA 
Wang (2014) [16] * * * NA NA NA NA NA 
Studies that assessed outcomeb 
Hayakawa (2012) [17] * No uninfected controls * * 
No uninfected 
controls * * - 
Hayakawa (2013) [18] * * * * * * * - 
Omotola (2013) [19] * * * * * * * - 
Britt (2015) [20] * No uninfected controls * * 
No uninfected 
controls * * * 
Song (2003) [21]c * * * * ** * * * 
Raad (2004) [22] * No uninfected controls * * 
No uninfected 
controls * * - 
DiazGranados (2005) 
[23] * 
No uninfected 
controls * * 
No uninfected 
controls * * * 
Gearhart (2005) [24] * * * * ** * * - 
Butler (2010) [25]c * * * * ** * * - 
Scheetz (2010) [26] * No uninfected controls * * 
No uninfected 
controls * * * 
Santayana (2012) [27] * No uninfected controls * * 
No uninfected 
controls * * * 
Vydra (2012) [28] * * * * * * * * 
Ford (2015) [29] * * * * ** * * * 
A star (*) indicates the study had a low risk of bias and high quality in that category. A maximum of 2 stars can be given for comparability category. NA = Not applicable because 
the study did not assess outcome. 
 
a. The 5 studies reporting incidence each had a low risk of bias in the selection of the study populations. 
b. The outcome studies had some risk of bias because 6 studies did not provide information about patients who were lost to follow up [17-19, 22, 24, 25]. 
c. The 2 studies reporting costs had low risk of bias because 1 study [25] met 14 of the 19 Consensus Health Economic Criteria [12] and another study met 17 criteria [21].  
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Table 2. Multicenter studies that evaluated incidence data on vancomycin-resistant enterococcal infections. 
First 
Author 
(Year) 
Study 
Population 
Study 
Period 
VRE Infection Type Number of VRE Infections Incidence Rate 
Camins 
(2007) [13] 
Atlanta 
population 
07/1997 – 
06/2000 
▪ Invasive VRE infections 
▪ Defined as VRE recovered from 
the blood, CSF, pleural fluid, 
pericardial fluid, synovial fluid, 
and sterile surgical sites 
192 
▪ 12 (6%) VR E. faecalis 
▪ 161 (83%) VR E. faecium 
▪ 74% Hospital-acquired (defined 
as VRE recovered >48  hours 
after admission) 
▪ 84% BSI 
Per 100,000 person-years 
All cohort 
▪ All years: 1.29; increasing trend P = 0.001 
▪ 1997 – 1998: 0.77 
▪ 1998 – 1999: 1.01 
▪ 1999 – 2000: 1.60 
African American 
▪ All years: 2.59; increasing trend P < 0.001 
▪ 1997 – 1998: 1.85 
▪ 1998 – 1999: 2.10 
▪ 1999 – 2000: 3.61 
White 
▪ All years: 0.70; increase was not significant 
▪ 1997 – 1998: 0.53 
▪ 1998 – 1999: 0.77 
▪ 1999 – 2000: 0.81 
First 
Author 
(Year) 
Study 
Population 
Study 
Period 
VRE Infection Type Number of VRE Infections Incidence Rate 
Hidron 
(2008) [2] 
Patients with 
catheters or 
central lines; 
data from 
National 
Healthcare 
Safety Network 
01/2006 – 
10/2007 
▪ Hospital-acquired CLABSI and 
CAUTI caused by VR E. faecium 
▪ Defined by CDC NHSN criteria 
▪ CLABSI: 384 VR E. faecium 
▪ CAUTI:  244 VR E. faecium 
 
VR E. faecium, per 1,000 device-days 
CLABSI 
▪ ICUs: pooled 0.18 (range 0.06 – 0.37) 
▪ Non-ICUs: pooled 0.14 (range 0.13 – 0.15) 
CAUTI  
▪ ICUs:  pooled  0.14 (range 0.05 – 0.18) 
▪ Non-ICUs:  pooled 0.25 (range 0.12 – 0.45) 
Hayakawa 
(2011) [14] 
Patients in 
Detroit Medical 
Center, 
southeast 
Michigan 
01/2003 – 
12/2009 
▪ VRE infections 
▪ Defined as VRE recovered from 
clinical specimens 
8,048 
▪ 2,322 (28.9%) VR E. faecalis  
▪ 5,726 (71.1%) VR E. faecium 
Per 1,000 patient-days 
VR E. faecalis 
▪ All years: 0.99; increasing trend P < 0.001 
▪ 2003: 0.72 
▪ 2004: 0.61 
▪ 2005: 0.72 
▪ 2006: 0.77 
▪ 2007: 1.09 
▪ 2008: 1.38 
▪ 2009: 1.68 
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Table 2. Continued. 
 
First 
Author 
(Year) 
Study 
Population 
Study 
Period 
VRE Infection Type Number of VRE Infections Incidence Rate 
Hayakawa 
(2011) - 
Continued 
    Per 1,000 patient-days 
VR E. faecium 
▪ All years: 2.43; did not increase significantly 
▪ 2003: 1.97 
▪ 2004: 2.14 
▪ 2005: 2.72 
▪ 2006: 2.75 
▪ 2007: 2.36 
▪ 2008: 2.47 
▪ 2009: 2.67 
Jain (2011) 
[15] 
Patients in 
Veterans Affairs 
hospitals 
10/2007 – 
06/2010 
▪ Hospital-acquired VRE 
infections 
▪ Defined as VRE recovered > 48 
hours after admission 
▪ Defined by CDC NHSN criteria 
Not provided Per 1,000 patient-days 
ICUs 
▪ All years: Decreasing trend P < 0.001 
▪ 2007: 1.51 
▪ 2010: 0.00 
Non-ICUs  
▪ All years: Decreasing trend P < 0.001 
▪ 2007: 0.33 
▪ 2010: 0.09 
Wang 
(2014) [16] 
Medicare 
patients ≥ 65 
years of age, 
with acute MI, 
CHF, 
pneumonia, or 
conditions 
requiring 
surgery;  
data from 
Medicare 
Patient Safety 
Monitoring 
System 
01/2005 – 
12/2007, 
01/2009 – 
12/2011 
▪ Hospital-acquired VRE 
infections 
▪ Defined as VRE recovered from 
sterile sites (blood, joint 
aspirates, pleural fluid, or 
peritoneal fluid) > 48 hours 
after admission 
29 Per 1,000 hospitalizations 
Acute MI 
▪ All years: 0; did not increase significantly 
▪ 2005 – 2006: 0 
▪ 2007 & 2009: 0 
▪ 2010 – 2011: 0 
CHF 
▪ All years: 0.26; did not increase significantly 
▪ 2005 – 2006 : 0 
▪ 2007 & 2009: 0.37 
▪ 2010 – 2011: 0.32 
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Table 2. Continued. 
BSI, bloodstream infection; CAUTI, catheter-associated urinary tract infection; CDC, Centers for Disease Control and Prevention; CHF, congestive heart failure; 
CLABSI, central-line associated bloodstream infection; ICU, intensive care unit; MI, myocardial infarction; NHSN, National Healthcare Safety Network; VRE, 
vancomycin-resistant enterococci. 
  
First 
Author 
(Year) 
Study 
Population 
Study 
Period 
VRE Infection Type Number of VRE Infections Incidence Rate 
Wang 
(2014) - 
Continued 
    Per 1,000 hospitalizations 
Pneumonia 
▪ All years: 0.66; did not increase significantly 
▪ 2005 – 2006: 0 
▪ 2007 & 2009: 0.41 
▪ 2010 – 2011: 0.96 
Conditions requiring surgery 
▪ All years: 0.76; did not decrease significantly 
▪ 2005 – 2006: 1.04 
▪ 2007 & 2009: 0.62 
▪ 2010 – 2011: 0.66 
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Table 3. Studies that evaluated outcomes attributable to vancomycin-resistant enterococcal (VRE) infections. 
 
First 
Author 
(Year) 
Study 
Population 
Study 
Period 
Number of 
Patients 
Mortality (%), 
OR (95% CI) 
Length of stay (LOS), 
median (IQR), days 
Discharge to a LTCF after 
being admitted from 
home (%), OR (95% CI) 
Readmissiona, 
OR (95% CI) 
Recurrent VRE 
infection (%) 
Costs, median (IQR), 
US dollars  
Multicenter Studies 
Patients with 
VR E. faecalis 
bacteremia, 
DMC 
01/2008 – 
10/2010 
105 patients 
with 
bacteremia 
- Overall 
▪ Post-infection: 
11.5 (7.0 – 21.6) 
▪ ICU post-infection 
LOS: 0.8 (0.0 – 11.8) 
 
Subgroup  of patients 
who survived during 
hospitalization:  
▪ Post-infection: 
    10.9 (7.2 – 21.8) 
- - - - 
Patients with 
VR E. faecium 
bacteremia, 
DMC 
01/2008 – 
10/2010 
197  patients 
with 
bacteremia 
- Overall 
▪ Post-infection: 
8.5 (4.2 – 18.4) 
▪  ICU post-infection 
LOS: 0.9 (0.0 – 6.1) 
 
Subgroup of patients 
who survived during 
hospitalization: 
▪ Post-infection:                   
9.1 (5.2 – 20.1) 
- - - - 
Hayakawa 
(2013) 
[18] 
Patients with 
VR E. faecalis  
vs  
uninfected 
patients,  
DMC 
01/2008 – 
12/2009 
532 patients 
with  VR E. 
faecalis 
(defined as 
VRE 
recovered 
from clinical 
specimens) 
were 
matched to 
532 
uninfected 
patientsb 
Overall 
▪ In-hospital:  
    9.8% vs 6.6%; 
    OR, 1.81  
    (1.06 –  3.08) 
▪ 90-dayc:  
    18.3% vs 10.1%; 
    OR, 2.58  
    (1.64 – 4.05) 
Overall 
▪ 11.4 (2.6 – 21.4) vs 
    4.2 (1.1 – 11.9); 
    P < 0.001 
▪ 7.2 days attributable 
to VRE infections 
 
Subgroup of patients 
who survived during 
hospitalization: 
▪ 6.6 (1.4 – 17.6) vs  
    2.0 (0.9 – 7.8); 
    P < 0.001 
▪ 4.6 days attributable 
to VRE infections 
Overall 
▪ 33.9% vs 11.4% 
    OR, 2.76 (1.68 – 4.55) 
Overall 
▪ 74.5% vs 50.8% 
    OR, 2.86 
    (2.12 – 3.87) 
- - 
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Table 3. Continued. 
 
 
First 
Author 
(Year) 
Study 
Population 
Study 
Period 
Number of 
Patients 
Mortality (%), 
OR (95% CI) 
Length of stay (LOS), 
median (IQR), days 
Discharge to a LTCF after 
being admitted from 
home (%), OR (95% CI) 
Readmissiona, 
OR (95% CI) 
Recurrent VRE 
infection (%) 
Costs, median (IQR), 
US dollars  
Omotola 
(2013) 
[19] 
Patients with 
community-
acquired          
VR E. faecalis 
infections 
vs  
uninfected 
patients, DMC 
01/2008 – 
12/2009 
289 patients 
with 
community-
acquired VR 
E. faecalis 
(defined as 
VRE 
recovered 
<48 hours 
after 
admission) 
were  
matched to 
289 
uninfected 
patientsb 
Overall 
▪ In-hospital: 
    9.1% vs 4.8%; 
    OR, 2.20  
    (1.04 – 4.65) 
▪ 90-dayc:  
    19.9% vs 6.8%; 
    OR, 5.00  
    (2.44 – 10.23) 
Overall 
▪ 5 (1 – 10) vs 2 (2 – 3); 
    P < 0.001 
▪ 3 days attributable to 
VRE infections 
Overall 
▪ 26.3% vs 4.7%;  
    OR, 6.50  
    (2.27 – 18.60) 
 
- - - 
Britt 
(2015) 
[20] 
Adult patients 
with VRE BSI 
who were 
treated with 
linezolid or 
daptomycin, 
Veterans Affairs 
hospitals 
1/2004 – 
1/2013 
644 patients 
with BSI:  
319 
linezolid-
treated;  
325 
daptomycin-
treated 
- Overall 
▪ Post-infection, after 
antibiotic treatment 
began: 13 (6 – 25) 
 
Subgroup 
▪ Linezolid-treated:  
    14 (7 – 25) 
▪ Daptomycin-treated:  
    12 (6 – 25) 
- - Overall 
▪ 60-day   
recurrence  
after antibiotic 
treatment 
began: 23.6% 
 
Subgroup of 
linezolid-treated 
patients: 
▪ 60-day   
recurrence: 
25.1% 
 
Subgroup of 
daptomycin-
treated patients: 
▪ 60-day   
recurrence: 
22.2% 
- 
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Table 3. Continued. 
 
First 
Author 
(Year) 
Study 
Population 
Study 
Period 
Number of 
Patients 
Mortality (%), 
OR (95% CI) 
Length of stay (LOS), 
median (IQR), days 
Discharge to a LTCF after 
being admitted from 
home (%), OR (95% CI) 
Readmissiona, 
OR (95% CI) 
Recurrent VRE 
infection (%) 
Costs, median (IQR), 
US dollars  
Single Center Studies 
Song  
(2003) 
[21] 
Patients with 
VRE bacteremia 
vs  
uninfected 
patients, Johns 
Hopkins 
Hospital 
01/1993 – 
12/2000 
277 patients 
with 
hospital-
acquired VRE 
bacteremia 
were 
matched to 
277 
uninfected 
patientsd 
Overall 
▪ 50.2% vs 19.9%;      
    P < 0.001 
▪ Adjusted ORe: 
    2.61  
    (1.43 – 4.75) 
 
Subgroup of 159 
pairs who had 
identical APR-DRG 
complexity level: 
▪ 50.3% vs 27.7% 
▪ Adjusted ORf,  
    3.04  
    (1.66 – 5.53) 
Overall 
▪ Total LOS: 
    42 vs 22 
▪ ICU LOS: 13 vs 1 
▪ Adjusted 
multiplicative 
increase (95% CI)g for 
total LOS:  
    1.44 (1.24 – 1.7) 
 
Subgroup of 159 pairs 
who had identical APR-
DRG complexity level: 
▪ Total LOS, 53 vs 28; 
▪ ICU LOS, 24 vs 7 
- - - Overall 
▪ Unadjusted: 
    $124,257 vs $46,699 
 
▪ Adjusted 
multiplicative 
increase (95% CI)h: 
    1.55 (1.32 – 1.84) 
 
Subgroup of 159 pairs 
who had identical 
APR-DRG complexity 
level: 
▪ Difference, $81,208 
Raad 
(2004) 
[22] 
Adult patients 
with cancer 
who  were 
treated with 
linezolid or 
quinupristin-
dalfopristin for 
VR E. faecium 
infection, 
University of 
Texas M.D. 
Anderson 
Cancer Center 
08/1998 – 
12/2001 
40 patients 
with 
hospital-
acquired VR 
E. faecium 
(defined by 
CDC NHSN):  
19 linezolid-
treated;  
21 
quinupristin-
dalfopristin-
treated  
- - - - Overall 
▪ 30-day 
recurrence 
after antibiotic 
treatment 
completed: 
15% 
 
Subgroup of 
linezolid-treated 
patients:  
▪ 30-day  
    recurrence:    
    21.1% 
 
Subgroup of 
Quinupristin-
dalfopristin -
treated patients:  
▪ 30-day  
    recurrence:  
    9.5% 
- 
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Table 3. Continued. 
 
 
 
First 
Author 
(Year) 
Study 
Population 
Study 
Period 
Number of 
Patients 
Mortality (%), 
OR (95% CI) 
Length of stay (LOS), 
median (IQR), days 
Discharge to a LTCF after 
being admitted from 
home (%), OR (95% CI) 
Readmissiona, 
OR (95% CI) 
Recurrent VRE 
infection (%) 
Costs, median (IQR), 
US dollars  
DiazGrana
dos 
(2005) 
[23] 
Patients with   
VRE BSI and 
neutropenia, 
Emory 
University 
Hospital in 
Atlanta 
11/1994 – 
01/2001 
22 patients 
with 
hospital-
acquired BSI 
(defined as 
VRE 
recovered > 
72 hours 
after 
admission) 
- Overall 
▪ Post-infection: 
    17 (range 0 – 52) 
- - - - 
Gearhart 
(2005) 
[24] 
Patients with 
VRE infections 
vs  
uninfected 
patients (all 
patients had 
liver 
transplants), 
University of 
Cincinnati 
1995 – 
2002 
19 infected 
patients,  
38 
uninfected 
patientsi 
Overall 
▪ 47.4% vs 18.4% 
▪ OR, 3.99 
    (1.18, 13.47) 
- - - - - 
Butler 
(2010) 
[25] 
Patients with 
VRE BSI 
vs 
uninfected 
patients, non-
surgical 
patients, 
Barnes-Jewish 
Hospital 
01/2002 – 
12/2003 
▪ 94 infected 
patients, 
20,150 
uninfected 
patients 
 
▪ 88 infected 
patients 
were  
matched to 
88 
uninfected 
patientsj 
- Overall 
▪ Unadjusted: 
    14.6 (7.3 – 28.3) vs 
    4.0 (2.9 – 6.2); 
    P < 0.001 
 
Subgroup of 88 pairs: 
▪ Difference (95% CI):  
    3.5 (2.1 – 7.3) 
- - - Overall 
▪ Unadjusted: 
    $42,106  
    ($16,310 – $93,870)  
    vs 
    $8,192  
    ($5,615 – $13,495) 
 
Subgroup of 88 pairs: 
▪ Difference (95% CI):  
    $9,949  
    ($1,579 – $24,693) 
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Table 3. Continued. 
 
 
 
First 
Author 
(Year) 
Study 
Population 
Study 
Period 
Number of 
Patients 
Mortality (%), 
OR (95% CI) 
Length of stay (LOS), 
median (IQR), days 
Discharge to a LTCF after 
being admitted from 
home (%), OR (95% CI) 
Readmissiona, 
OR (95% CI) 
Recurrent VRE 
infection (%) 
Costs, median (IQR), 
US dollars  
Single Center Studies 
Scheetz 
(2010) 
[26] 
Adult patients 
with                
VR E. faecium 
infections, 
Northwestern 
Memorial 
Hospital, 
Chicago 
2002 - 
2007 
72 infected 
patients 
(defined as  
VR E. 
faecium  
recovered 
from clinical 
specimens): 
18 isolates 
were 
linezolid-
resistant or –
intermediate 
and 54 
isolates were 
linezolid-
susceptible 
- Subgroup of patients 
with  linezolid-resistant 
or –intermediate VRE: 
▪ Post-infection LOS 
    13 (3 – 21) 
 
Subgroup of patients 
with  linezolid-
susceptible VRE: 
▪ Post-infection LOS 
    9 (3 – 16) 
- - - - 
Santayana 
(2012) 
[27] 
Adult patients 
with VRE 
infections, 
University of 
Chicago 
Medical Center 
01/2000 – 
09/2008 
144 infected 
patients 
(defined as 
VRE 
recovered 
from sterile 
sites):  
48 isolates 
were 
linezolid-
resistant or –
intermediate 
and 96 
isolates were 
linezolid-
susceptible 
- Subgroup of patients 
with  linezolid-resistant 
or –intermediate VRE: 
▪ Post-infection LOS, 
    mean 22 
 
Subgroup of patients 
with  linezolid-
susceptible VRE: 
▪ Post-infection LOS, 
    mean 19 
- - - - 
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Table 3. Continued. 
APR-DRG, All Patient Refined-Diagnosis Related Group; BSI, bloodstream infection; CI, confidence interval; DMC, Detroit Medical Center; HR, hazard ratio; ICU, 
intensive care unit; IQR, interquartile range; LTCF, long-term care facility; OR, odds ratio; VRE, vancomycin-resistant enterococci. 
a. Readmissions within 6 months following VRE isolation for infected patients or within 6 months after admission for uninfected patients. 
b. VRE infected patients and uninfected patients were matched by hospital or outpatient facility, unit or clinic, calendar year, and time at risk (i.e., time from 
admission to culture for infected patients, time from admission to discharge for uninfected patients). 
First 
Author 
(Year) 
Study 
Population 
Study 
Period 
No. of 
Patients 
Mortality (%), 
OR (95% CI) 
Length of stay (LOS), 
median (IQR), days 
Discharge to a LTCF after 
being admitted from 
home (%), OR (95% CI) 
Readmissiona, 
OR (95% CI) 
Recurrent VRE 
infection (%) 
Costs, median (IQR), 
US dollars  
Single Center Studies 
Vydra 
(2012) 
[28] 
Patients with 
VRE bacteremia 
vs  
uninfected 
patients, 
recipients of 
allogeneic 
hematopoietic 
stem cell 
transplantation, 
University of 
Minnesota 
01/2004 – 
12/2008 
50 patients 
with VRE 
bacteremia, 
659 
uninfected 
patients 
Overall 
▪ 1-year non- 
    relapse  
    mortalityk: 
    48% vs 19.6% 
▪ Adjusted HRl: 
    4.2 (3.1 – 6.9) 
 
Subgroup of adult 
patients: 
▪ 53% vs 22%  
▪ OR, 3.90  
    (2.01 – 7.55) 
 
Subgroup of 
pediatric patients: 
▪ 30% vs 15%  
▪ OR, 2.46  
    (0.61 – 9.97) 
- - - - - 
Ford 
(2015) 
[29] 
Adult patients 
with VRE BSI  
vs  
uninfected 
patients,  
with newly 
diagnosed 
acute 
myelogenous 
or acute 
lymphoblastic 
leukemia,  
LDS Hospital,  
Salt Lake City, 
Utah 
10/2006 – 
12/2012 
15 infected 
patients 
were 
matched to 
45 
uninfected 
patientsm 
Overall 
▪ 60-day mortality:  
    33% vs 18% 
▪ HR, 1.9  
    (0.87 – 5.1) 
- - - - - 
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c. Deaths within 90 days after VRE isolation for infected patients or within 90 days after admission for uninfected patients. 
d. Patients with VRE BSI and uninfected patients were matched on time at risk and at least 3 of the following criteria: age (± 10 years), calendar year (± 2 
years), principal ICD-9 diagnosis code at admission, primary ICD-9 procedure code during hospitalization, or APR-DRGs. 
e. Adjusted for severe illness (APR-DRG complexity level 4), being transferred from another healthcare facility, and staying in an ICU. 
f. Adjusted for being transferred from another healthcare facility. 
g. Adjusted for severe illness (APR-DRG complexity level 4). 
h. Adjusted for severe illness (APR-DRG complexity level 4) and staying in an ICU. 
i. VRE infected patients and uninfected patients were matched (1:2) by age, gender, underlying disease, United Network for Organ Sharing status, primary or 
re-transplant, transplant date. 
j. Patients with VRE BSI and uninfected patients were matched based on their propensity to develop VRE BSI (propensity scores matching). 
k. Non-relapse mortality is defined as deaths which could not be attributed to disease relapse or progression. 
l. Adjusted for acute graft-vs-host disease (GVHD), chronic GVHD, engrafted by day 42, age, sex, diagnosis, cytomegalovirus, donor type, and Karnofsky 
performance score. 
m. VRE infected patients and uninfected patients were matched (1:3) by leukemia type, age, admitting Karnofsky performance status, and initial treatment 
regimen. 
 
 
